BRAF-Inhibitors, In-licensing others
Contact us to add description: email@example.com
Fore Biotherapeutics is using precision oncology to develop innovative treatments for cancer patients. Current existing cancer drugs target the most common cancer-triggering mutations, however, most mutations in cancer are infrequent, understudied and unaddressed. Fore is using their high-throughout, high-precision functional genomics approach to find therapeutic options for patients whose cancers are driven by a multitude of rarer cancer-triggering mutations. This involves identifying targets and matching them to candidate compounds that can reduce oncogenic signaling pathways. Fore’s lead program, FORE8394, is a small molecule inhibitor of mutated BRAF that is being investigated for CNS and solid tumors.